Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells

Hiroya Kobayashi, Toshihiro Nagato, Miki Takahara, Keisuke Sato, Shoji Kimura, Naoko Aoki, Makoto Azumi, Masatoshi Tateno, Yasuaki Harabuchi, Esteban Celis

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

EBV-encoded latent membrane protein 1 (LMP1) has oncogenic potential and is expressed in many EBV-associated malignancies. Although LMP1 is regarded as a potential tumor-associated antigen for immunotherapy and several LMP1-specific MHC class I-restricted CTL epitopes have been reported, little is known regarding MHC class II-restricted CD4 helper T-lymphocyte (HTL) epitopes for LMP1. The goal ofthe present studies was to determine whether MHC class II-restricted CD4 T-cell responses could be induced against the LMP1 antigen and to evaluate the antitumor effect of these responses. We have combined the use ofa predictive MHC class II binding peptide algorithm with in vitro vaccination of CD4 T cells using candidate peptides to identify naturally processed epitopes derived from LMP1 that elicit immune responses against EBV-expressing tumor cells. Peptide LMP1159-175 was effective in inducing HTL responses that were restricted by HLA-DR9, HLA-DR53, or HLA-DR15, indicating that this peptide behaves as a promiscuous T-cell epitope. Moreover, LMP1 159-175-reactive HTL clones directly recognized EBV lymphoblastoid B cells, EBV-infected natural killer (NK)/T-lymphoma cells and naturally processed antigen in the form of LMP1+ tumor cell lysates presented by autologous dendritic cells. Because the newly identified epitope LMP1159-175 overlaps with an HLA-A2-restricted CTL epitope (LMP1159-167), this peptide might have the ability to induce simultaneous CTL and HTL responses against LMP1. Overall, our data should be relevant for the design and optimization of T-cell epitope-based immunotherapy against various EBV-associated malignancies, including NK/T cell lymphomas.

Original languageEnglish (US)
Pages (from-to)901-908
Number of pages8
JournalCancer Research
Volume68
Issue number3
DOIs
StatePublished - Feb 1 2008
Externally publishedYes

Fingerprint

Human Herpesvirus 4
Natural Killer Cells
Lymphoma
Membrane Proteins
T-Lymphocytes
Helper-Inducer T-Lymphocytes
T-Lymphocyte Epitopes
Epitopes
Peptides
Natural Killer T-Cells
Immunotherapy
Neoplasms
HLA-A2 Antigen
Antigens
T-Cell Lymphoma
Neoplasm Antigens
Dendritic Cells
Vaccination
B-Lymphocytes
Clone Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. / Kobayashi, Hiroya; Nagato, Toshihiro; Takahara, Miki; Sato, Keisuke; Kimura, Shoji; Aoki, Naoko; Azumi, Makoto; Tateno, Masatoshi; Harabuchi, Yasuaki; Celis, Esteban.

In: Cancer Research, Vol. 68, No. 3, 01.02.2008, p. 901-908.

Research output: Contribution to journalArticle

Kobayashi, H, Nagato, T, Takahara, M, Sato, K, Kimura, S, Aoki, N, Azumi, M, Tateno, M, Harabuchi, Y & Celis, E 2008, 'Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells', Cancer Research, vol. 68, no. 3, pp. 901-908. https://doi.org/10.1158/0008-5472.CAN-07-3212
Kobayashi, Hiroya ; Nagato, Toshihiro ; Takahara, Miki ; Sato, Keisuke ; Kimura, Shoji ; Aoki, Naoko ; Azumi, Makoto ; Tateno, Masatoshi ; Harabuchi, Yasuaki ; Celis, Esteban. / Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. In: Cancer Research. 2008 ; Vol. 68, No. 3. pp. 901-908.
@article{29ea06017c8f4b13a3496f7360c62440,
title = "Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells",
abstract = "EBV-encoded latent membrane protein 1 (LMP1) has oncogenic potential and is expressed in many EBV-associated malignancies. Although LMP1 is regarded as a potential tumor-associated antigen for immunotherapy and several LMP1-specific MHC class I-restricted CTL epitopes have been reported, little is known regarding MHC class II-restricted CD4 helper T-lymphocyte (HTL) epitopes for LMP1. The goal ofthe present studies was to determine whether MHC class II-restricted CD4 T-cell responses could be induced against the LMP1 antigen and to evaluate the antitumor effect of these responses. We have combined the use ofa predictive MHC class II binding peptide algorithm with in vitro vaccination of CD4 T cells using candidate peptides to identify naturally processed epitopes derived from LMP1 that elicit immune responses against EBV-expressing tumor cells. Peptide LMP1159-175 was effective in inducing HTL responses that were restricted by HLA-DR9, HLA-DR53, or HLA-DR15, indicating that this peptide behaves as a promiscuous T-cell epitope. Moreover, LMP1 159-175-reactive HTL clones directly recognized EBV lymphoblastoid B cells, EBV-infected natural killer (NK)/T-lymphoma cells and naturally processed antigen in the form of LMP1+ tumor cell lysates presented by autologous dendritic cells. Because the newly identified epitope LMP1159-175 overlaps with an HLA-A2-restricted CTL epitope (LMP1159-167), this peptide might have the ability to induce simultaneous CTL and HTL responses against LMP1. Overall, our data should be relevant for the design and optimization of T-cell epitope-based immunotherapy against various EBV-associated malignancies, including NK/T cell lymphomas.",
author = "Hiroya Kobayashi and Toshihiro Nagato and Miki Takahara and Keisuke Sato and Shoji Kimura and Naoko Aoki and Makoto Azumi and Masatoshi Tateno and Yasuaki Harabuchi and Esteban Celis",
year = "2008",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-07-3212",
language = "English (US)",
volume = "68",
pages = "901--908",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells

AU - Kobayashi, Hiroya

AU - Nagato, Toshihiro

AU - Takahara, Miki

AU - Sato, Keisuke

AU - Kimura, Shoji

AU - Aoki, Naoko

AU - Azumi, Makoto

AU - Tateno, Masatoshi

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

PY - 2008/2/1

Y1 - 2008/2/1

N2 - EBV-encoded latent membrane protein 1 (LMP1) has oncogenic potential and is expressed in many EBV-associated malignancies. Although LMP1 is regarded as a potential tumor-associated antigen for immunotherapy and several LMP1-specific MHC class I-restricted CTL epitopes have been reported, little is known regarding MHC class II-restricted CD4 helper T-lymphocyte (HTL) epitopes for LMP1. The goal ofthe present studies was to determine whether MHC class II-restricted CD4 T-cell responses could be induced against the LMP1 antigen and to evaluate the antitumor effect of these responses. We have combined the use ofa predictive MHC class II binding peptide algorithm with in vitro vaccination of CD4 T cells using candidate peptides to identify naturally processed epitopes derived from LMP1 that elicit immune responses against EBV-expressing tumor cells. Peptide LMP1159-175 was effective in inducing HTL responses that were restricted by HLA-DR9, HLA-DR53, or HLA-DR15, indicating that this peptide behaves as a promiscuous T-cell epitope. Moreover, LMP1 159-175-reactive HTL clones directly recognized EBV lymphoblastoid B cells, EBV-infected natural killer (NK)/T-lymphoma cells and naturally processed antigen in the form of LMP1+ tumor cell lysates presented by autologous dendritic cells. Because the newly identified epitope LMP1159-175 overlaps with an HLA-A2-restricted CTL epitope (LMP1159-167), this peptide might have the ability to induce simultaneous CTL and HTL responses against LMP1. Overall, our data should be relevant for the design and optimization of T-cell epitope-based immunotherapy against various EBV-associated malignancies, including NK/T cell lymphomas.

AB - EBV-encoded latent membrane protein 1 (LMP1) has oncogenic potential and is expressed in many EBV-associated malignancies. Although LMP1 is regarded as a potential tumor-associated antigen for immunotherapy and several LMP1-specific MHC class I-restricted CTL epitopes have been reported, little is known regarding MHC class II-restricted CD4 helper T-lymphocyte (HTL) epitopes for LMP1. The goal ofthe present studies was to determine whether MHC class II-restricted CD4 T-cell responses could be induced against the LMP1 antigen and to evaluate the antitumor effect of these responses. We have combined the use ofa predictive MHC class II binding peptide algorithm with in vitro vaccination of CD4 T cells using candidate peptides to identify naturally processed epitopes derived from LMP1 that elicit immune responses against EBV-expressing tumor cells. Peptide LMP1159-175 was effective in inducing HTL responses that were restricted by HLA-DR9, HLA-DR53, or HLA-DR15, indicating that this peptide behaves as a promiscuous T-cell epitope. Moreover, LMP1 159-175-reactive HTL clones directly recognized EBV lymphoblastoid B cells, EBV-infected natural killer (NK)/T-lymphoma cells and naturally processed antigen in the form of LMP1+ tumor cell lysates presented by autologous dendritic cells. Because the newly identified epitope LMP1159-175 overlaps with an HLA-A2-restricted CTL epitope (LMP1159-167), this peptide might have the ability to induce simultaneous CTL and HTL responses against LMP1. Overall, our data should be relevant for the design and optimization of T-cell epitope-based immunotherapy against various EBV-associated malignancies, including NK/T cell lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=38849166751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849166751&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-3212

DO - 10.1158/0008-5472.CAN-07-3212

M3 - Article

VL - 68

SP - 901

EP - 908

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -